Akero Therapeutics, Inc.
AKRO
$41.00
$0.010.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.96% | 18.67% | 36.30% | 33.56% | 19.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.11% | 75.27% | 84.52% | 108.51% | 143.40% |
| Operating Income | -26.11% | -75.27% | -84.52% | -108.51% | -143.40% |
| Income Before Tax | -26.89% | -83.33% | -80.12% | -106.51% | -139.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.89% | -83.33% | -80.12% | -106.51% | -139.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.89% | -83.33% | -80.12% | -106.51% | -139.33% |
| EBIT | -26.11% | -75.27% | -84.52% | -108.51% | -143.40% |
| EBITDA | -26.08% | -75.29% | -84.57% | -108.59% | -143.49% |
| EPS Basic | -0.17% | -46.82% | -35.07% | -63.44% | -100.87% |
| Normalized Basic EPS | 4.02% | -46.83% | -35.11% | -63.48% | -77.98% |
| EPS Diluted | -0.17% | -46.82% | -35.00% | -63.44% | -100.87% |
| Normalized Diluted EPS | 4.02% | -46.83% | -35.11% | -63.48% | -77.98% |
| Average Basic Shares Outstanding | 26.66% | 24.87% | 33.34% | 26.34% | 19.15% |
| Average Diluted Shares Outstanding | 26.66% | 24.87% | 33.34% | 26.34% | 19.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |